Pseudotype-Based Neutralization Assay
The outbreak of 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of vaccines capable of inducing neutralizing antibodies (NAbs) is a key goal to control the global COVID-19 pandemic. However, the novel coronavirus SARS-CoV-2 is highly contagious and highly pathogenic, presenting tremendous difficulties for neutralization evaluation of drug candidates and vaccines.
To address this issue, Creative Bioarray offers Pseudotype-Based Neutralization Assay service to evaluate neutralizing antibodies against SARS-CoV-2. Pseudotype-based neutralization assay employs pseudovirus as an alternative to wild-type SARS-CoV-2. The infectivity of pseudotyped SARS-CoV-2 is limited to a single round of replication. Thus, pseudovirus can be handled in BSL-2 facilities. Pseudotype-based method enables safe and rapid neutralization analysis to study functional antibody response against coronaviruses.
Fig.1 Competition of NAbs with ACE2 for binding to the spike protein of SARS-CoV-2.
Pseudotype-Based Neutralization Assay
Creative Bioarray uses hACE2 stable cell lines as in vitro models for neutralization assay. As the fluorescence or luciferase level is correlated to the extent of pseudovirus infection, neutralizing potency of test substance can be quantified by measuring the reduction of signals in NAb-treated cells compared to non-treated control. This method is preferable than the conventional method due to its safety, superior sensitivity, reproductivity and high throughput capacity.
Related Products for Neutralization Assay
- Pseudoviruses
Compared with infectious SARS-CoV-2, pseudovirus is a biologically safe, reliable and effective tool for COVID-19 studies. Pseudovirus can be processed with safety, has extensive host ranges, and exhibits high competency of transfection in cells.
Cat # | Product Name |
CoV-001 | SARS-CoV-2 S Pseudotyped GFP Lentivirus |
CoV-002 | SARS-CoV-2 S Pseudotyped Luciferase Lentivirus |
CoV-009 | SARS-CoV-2 S Pseudotyped mCherry Lentivirus |
CoV-010 | VSV-SARS-CoV2 S-deltaG-mCherry |
CoV-011 | AAV-SARS-CoV2 S-GFP |
CoV-003 | SARS-CoV-2 E Pseudovirus |
CoV-004 | SARS-CoV-2 M Pseudovirus |
CoV-005 | SARS-CoV-2 N Pseudovirus |
CoV-006 | SARS-CoV-2 abEN Pseudovirus |
CoV-007 | SARS-CoV-2 abMEN Pseudovirus |
CoV-008 | SARS-CoV-2 abSMEN Pseudovirus |
- hACE2 Stable Cell Line
Creative Bioarray offers various stable cell lines overexpressing human ACE2 genes, which have been validated and can be used for in vitro neutralization assays to screen potential NAbs or drug candidates.
Cat # | Product Name | Description |
CSC-RO0292 | hACE2 Stable Cell Line - HEK293 | Human Embryonic Kidney-Derived Cell Line |
CSC-RO0641 | hACE2 Stable Cell Line - HEK293T | Human Embryonic Kidney-Derived Cell Line |
CSC-RO0289 | hACE2 Stable Cell Line - HeLa | Human Cervical Cancer Cell-Derived Cell Line |
CSC-RO0293 | hACE2 Stable Cell Line - CHO-K1 | Chinese Hamster Ovary-Derived Cell Line |
CSC-RO0291 | hACE2 Stable Cell Line - NIH-3T3 | Mouse Embryonic Fibroblast-Derived Cell Line |
CSC-RO0642 | hACE2 Stable Cell Line - A549 | Human Lung Carcinoma-Derived Cell Line |
CSC-RO0290 | hACE2 Stable Cell Line - COS7 | Monkey Kidney Fibroblast-Derived Cell Line |
CSC-RO0645 | hACE2 Stable Cell Line - Vero | Monkey Kidney Cell Line |
CSC-RO0646 | hACE3 Stable Cell Line - BHK | Hamster Kidney Fibroblast Cell Line |
Feel free to contact us
If you are interested in our pseudotype-based neutralization service or related product, contact us today to get more info. Our scientists would be happy to answer your questions. Please let us know your research interests. We are looking forward to working with you.
References
- Zhou G, et al., Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020 Mar 15;16(10):1718-1723.
- Shanmugaraj B, et al., Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 38.1 (2020): 10-18.
- Wang, Chunyan, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications 11.1 (2020): 1-6.